James Molloy

Claire Adison

Joanne Lee

Matthew Keller

Wing Yip

- **Acurx Pharmaceuticals** announced that the **Australian Patent Office** granted a new patent for **DNA Polymerase IIIC Inhibitors**, which relates to compositions-of-matter and expands the company's intellectual property portfolio.  **[1736243_20251009NY94088:0]** 
- This new patent adds to Acurx's existing patents, which include **three U.S. patents, one Israeli patent, one Japanese patent, and one Indian patent**, all covering the ACX-375C program.  **[1736243_20251009NY94088:0]** 
- The company believes these new compounds have the potential to transform antibiotic treatment for **multidrug-resistant Gram-positive pathogens** such as MRSA, VRE, and PRSP, and are expected to be active against **B. anthracis (anthrax)**.  **[1736243_20251009NY94088:0]** 
- Acurx's lead DNA pol IIIC inhibitor, **ibezapolstat**, is **Phase 3-ready** for oral treatment of *C. difficile* Infection, while preclinical compounds are being developed for **Acute Bacterial Skin and Skin Structure Infections (ABSSSI)** and **inhaled anthrax**.  **[1736243_20251009NY94088:0]**

Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors

- **Acurx Pharmaceuticals** has received a **positive opinion** from the European Medicines Agency's (EMA) Paediatric Committee (PDCO) on its **Pediatric Investigation Plan (PIP)** for **ibezapolstat** for _C. difficile_ infection (CDI) in children.  **[1736243_20250930NY86075:0]** 
- This positive opinion fulfills the EMA's requirement for an agreed PIP before initiating **ibezapolstat Phase 3 clinical trials** in the European Union.  **[1736243_20250930NY86075:0]** 
- Ibezapolstat, a **novel, orally administered antibiotic** and the first of a new class of **DNA polymerase IIIC inhibitors**, has also received **FDA Qualified Infectious Disease Product (QIDP)** and **Fast-Track Designation**, and **EMA Small and Medium-sized Enterprise (SME) designation**.  **[1736243_20250930NY86075:0]** **[1736243_20250930NY86075:3]** 
- Successful development could lead to an **additional one year of marketing exclusivity in Europe** for ibezapolstat, on top of the standard 10 years for a new class of antibiotic.  **[1736243_20250930NY86075:0]**

Acurx Pharmaceuticals (ACXP)